SAN DIEGO–(BUSINESS WIRE)–Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced a target discovery collaboration with Ono Pharmaceutical Co., Ltd. focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Under the agreement, Sinopia will apply its proprietary metabolomics-driven discovery platform to identify and validate novel
Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders
